Skip to main content
VERTEX PHARMACEUTICALS INC / MA logo

VERTEX PHARMACEUTICALS INC / MA — Investor Relations & Filings

Ticker · VRTX ISIN · US92532F1003 LEI · 54930015RAQRRZ5ZGJ91 US Manufacturing
Filings indexed 2,379 across all filing types
Latest filing 2025-02-11 Regulatory Filings
Country US United States of America
Listing US VRTX

About VERTEX PHARMACEUTICALS INC / MA

https://www.vrtx.com/

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to discover, develop, and commercialize transformative medicines for serious diseases. The company is a leader in the field of cystic fibrosis (CF), having developed multiple therapies that treat the underlying cause of the disease for a significant portion of patients. Beyond its focus on CF, Vertex is advancing a research and development pipeline that includes potential treatments for other serious conditions such as sickle cell disease, beta-thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, and type 1 diabetes. The company's strategy is centered on a deep understanding of human biology to address the root cause of illness.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-02-11 English
Regulatory Filings 2025
Regulatory Filings
2025-02-11 English
Regulatory Filings 2025
Regulatory Filings
2025-02-11 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text includes an Item 2.02 reporting the issuance of a press release with financial results for the quarter and year ended December 31, 2024, but the actual financial results are in the attached press release (Exhibit 99.1), not in the 8-K text itself. The document also includes Item 5.02 announcing changes in senior management, specifically the retirement of an executive and appointments of new officers, with detailed biographical and compensation information. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple earnings release since it includes management changes. The primary content is management changes and related agreements, which fits the Board/Management Information (MANG) category. The presence of financial results mentioned is secondary and only via a press release attachment, not the report itself. Therefore, the best classification is MANG with high confidence.
2025-02-10 English
FORM 4
Director's Dealing
2025-02-06 English
FORM 4
Director's Dealing
2025-02-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.